

# References

---

1. Block, S.L., et al., *Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women*. *Pediatrics*, 2006. **118**(5): p. 2135-45.
2. Bosch FX, et al., *The causal relation between human papillomavirus and cervical cancer* *Journal of Clinical Pathology*, 2002. **55**: p. 244-265.
3. Burd, E.M., *Human papillomavirus and cervical cancer*. *Clinical Microbiology Reviews*, 2003. **16**(1): p. 1-17.
4. Castellsague, X., et al., *Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners*. *New England Journal of Medicine*, 2002. **346**(15): p. 1105-12.
5. Castellsague, X. and N. Munoz, *Chapter 3: Cofactors in human papillomavirus carcinogenesis--role of parity, oral contraceptives, and tobacco smoking*. *Journal of the National Cancer Institute*, 2003. **Monographs**.(31): p. 20-8.
6. Centers for Disease Control and Prevention. *Genital HPV infection Fact Sheet*. 2004 [cited 2004 September]; Available from: <http://www.cdc.gov/std/HPV/hpv.pdf>.
7. Collins, S., et al., *High incidence of cervical human papillomavirus infection in women during their first sexual relationship*. *BJOG: An International Journal of Obstetrics & Gynaecology*, 2002. **109**(1): p. 96-8.
8. Fairley, C.K., et al., *Hand-genital transmission of genital warts? An analysis of prevalence data*. *Epidemiology & Infection*, 1995. **115**(1): p. 169-76.
9. Ferenczy, A., C. Bergeron, and R.M. Richart, *Human papillomavirus DNA in fomites on objects used for the management of patients with genital human papillomavirus infections*. *Obstetrics & Gynecology*, 1989. **74**(6): p. 950-4.
10. Food and Drug Administration, *Clinical Review of Biologics License Application for Human Papillomavirus 6, 11, 16, 18 L1 Virus Like Particle Vaccine (S. cerevisiae) (STN 125126 GARDASIL), manufactured by Merck, Inc, D.o.V.a.R.P.A. Vaccines Clinical Trial Branch, Office of Vaccines Research and Review, Centre for Biologics Evaluation and Research, Editor*. 2006, Food and Drug Administration.
11. Future II Study Group, *Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection.[see comment]*. *Journal of Infectious Diseases*, 2007. **196**(10): p. 1438-46.
12. Garland, S.M., et al., *Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.[see comment]*. *New England Journal of Medicine*, 2007. **356**(19): p. 1928-43.
13. Greer CE, et al., *Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts*. *Journal of Clinical Microbiology*, 1995. **33**: p. 2058-2063.
14. Herrero, R., et al., *Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study*. *Journal of the National Cancer Institute*, 2003. **95**(23): p. 1772-83.

15. Institute of Environmental Science and Research, *Sexually Transmitted Infections in New Zealand. Annual Surveillance Report 2006*, ESR, Editor. 2007: Wellington.
16. Kashima, H.K., P. Mounts, and K. Shah, *Recurrent respiratory papillomatosis*. *Obstetrics & Gynecology Clinics of North America*, 1996. **23**(3): p. 699-706.
17. Kjaer, S.K., et al., *High-risk human papillomavirus is sexually transmitted: evidence from a follow-up study of virgins starting sexual activity (intercourse)*. *Cancer Epidemiology, Biomarkers & Prevention*, 2001. **10**(2): p. 101-6.
18. Koutsky, L., *Epidemiology of genital human papillomavirus infection*. *American Journal of Medicine*, 1997. **102**(5A): p. 3-8.
19. Koutsky, L.A., et al., *A controlled trial of a human papillomavirus type 16 vaccine*. *New England Journal of Medicine*, 2002. **347**(21): p. 1645-51.
20. Manhart, L.E. and L.A. Koutsky, *Do condoms prevent genital HPV infection, external genital warts, or cervical neoplasia? A meta-analysis*. *Sexually Transmitted Diseases*, 2002. **29**(11): p. 725-35.
21. Markowitz, L.E., et al., *Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP)*. *Morbidity & Mortality Weekly Report*, 2007. **Recommendations & Reports**. **56**(RR-2): p. 1-24.
22. Merck & Co Inc, *Recombivax HB® Hepatitis B Vaccine (Recombinant) prescribing information*. 1998: Whitehouse Station, NJ.
23. Ministry of Health, *The HPV (Human Papillomavirus) Immunisation Programme National Implementation Strategic Overview*, P.H.D.M.o. Health, Editor. 2008, Ministry of Health: Wellington.
24. Munoz, N., et al., *Against which human papillomavirus types shall we vaccinate and screen? The international perspective.[see comment]*. *International Journal of Cancer*, 2004. **111**(2): p. 278-85.
25. Robson, B. and R.e. Harris, *Hauora: Māori standards of Health IV. A study of the years 2000-2005*. 2007, Te Ropu Rangahau Hauora a Eru Pomare.: Wellington.
26. Roden, R., A. Monie, and T.C. Wu, *The impact of preventive HPV vaccination*. *Discovery Medicine*, 2006. **6**(35): p. 175-81.
27. Smith, E.M., et al., *Human papillomavirus prevalence and types in newborns and parents: concordance and modes of transmission*. *Sexually Transmitted Diseases*, 2004. **31**(1): p. 57-62.
28. Thomas SM and Croxson MC, *Genital Papillomavirus Genotypes in Auckland, New Zealand. (Poster presentation)*, in *22nd HPV Conference 2005*. 2005.: Vancouver, Canada.
29. Villa, L.L., et al., *Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial*. *Lancet Oncology*, 2005. **6**(5): p. 271-8.
30. Villa, L.L., et al., *High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up*. *British Journal of Cancer*, 2006. **95**(11): p. 1459-66.
31. Winer, R.L., et al., *Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students*. *American Journal of Epidemiology*, 2003. **157**(3): p. 218-26.

32. World Health Organization, *Sexually transmitted infections increasing: 250 million new infections annually*, in *WHO Features*, W.O.o. Information, Editor. 1990, World Health Organization: Geneva. p. 1-17.
33. World Health Organization, *The current status of development of prophylactic vaccines against human papillomavirus infection: report of a technical meeting*. 1999, World Health Organization: Geneva. p. 1-22